Spyre Therapeutics, Inc. SYRE Proceeds From Sale And Maturity Of Available For Sale Securities
Proceeds From Sale And Maturity Of Available For Sale Securities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
- Spyre Therapeutics, Inc. (SYRE) reported proceeds from sale and maturity of available for sale securities of $107.75M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
- Spyre Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities increased by 50.9% year-over-year, from $71.38M to $107.75M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a 35.3% compound annual growth rate (CAGR), from $111.03M to $371.74M.